The Rise, Bankruptcy and Rebirth of 23andMe | The Circuit

Key Concepts

• 23andMe: A personal genetics company that provides consumer genetic testing and conducts research on human health and disease.
• Nonprofit Restructuring: The strategic shift of 23andMe from a public, for-profit entity to a mission-driven nonprofit organization.
• Personalized Prevention: The long-term goal of using genetic data to create individualized health plans to eliminate preventable diseases.
• MAHA Movement: "Make America Healthy Again," a movement focused on skepticism toward the traditional medical establishment and advocacy for personal health autonomy.
• Data Privacy: The challenge of managing sensitive genetic information, particularly following a 2023 incident involving credential stuffing (often mislabeled as a "data breach").
• Willful Ignorance of Constraints: A Silicon Valley term describing the ability to pursue ambitious goals despite significant obstacles or skepticism.

---

1. The Evolution of 23andMe

Anne Wojcicki, co-founder and CEO, describes the current state of 23andMe as an "evolution" rather than a simple comeback. After the company’s stock plummeted from a $5.7 billion market cap and it faced bankruptcy, Wojcicki bought the company back for $35 million in cash.

• Strategic Shift: The company is moving away from the pressures of Wall Street to focus on its original mission: becoming an open science platform for the world to make discoveries about the foundations of life, including oncology, immunology, neurology, and cardiovascular health.
• Business Model: As a nonprofit, the company will rely on kit sales, donations, and research partnerships. It aims to scale its database from 13 million to hundreds of millions of users to leverage AI for medical breakthroughs.

2. Challenges and Controversies

Wojcicki’s tenure has been marked by significant hurdles:

• The "Data Breach" Clarification: Wojcicki clarifies that the 2023 incident was not a system breach but a "credential stuffing" attack where hackers used passwords from other sites to access 13,000–14,000 accounts. The company notified all genetically connected individuals, leading to a perception of a larger-scale breach.
• Board Resignation: In 2024, the board resigned en masse, citing disagreements over strategic direction. Wojcicki describes this as a "complicated" period, noting that the resignation occurred shortly after the death of her sister, Susan Wojcicki.
• The Regeneron Auction: During the bankruptcy process, Regeneron initially won the auction for 23andMe’s assets. Wojcicki successfully petitioned the court to reopen the auction, arguing that keeping the data within 23andMe was essential to prevent it from being absorbed by Big Pharma.

3. Personal Philosophy and Resilience

Wojcicki attributes her resilience to her upbringing in an "illustrious" family, including her mother, Esther (a renowned educator), and her late sister, Susan (former CEO of YouTube).

• The "Master’s in Hard Things": Wojcicki notes that she has learned to process professional and personal trauma—including the deaths of her father, her sister Susan, and her nephew Marco—by focusing on daily habits, such as cycling, which she describes as her "freedom."
• Advocacy: Influenced by her mother’s experience with a family tragedy, Wojcicki emphasizes the importance of self-advocacy in healthcare. She aligns with the sentiment of the "MAHA" movement, noting that many people feel unheard by the current medical system.

4. Notable Quotes

• On the mission: "23andMe, I think, is so incredibly valuable and it's now a gift to society. And so, this should be the open science platform for the world."
• On failure: "I think the thing that I learned from [Google] and from like frankly like this whole culture is that it's okay to try and it's okay to fail."
• On resilience: "We couldn't control Susan getting sick. We couldn't control Marco dying. Like I couldn't control aspects of 23andMe. And so the thing I can control is like making myself happy and optimistic."

5. Synthesis and Conclusion

Anne Wojcicki’s journey with 23andMe represents a high-stakes pivot from a public biotech darling to a mission-focused nonprofit. Despite facing a public collapse, a data security crisis, and profound personal loss, Wojcicki remains committed to the goal of "personalized prevention." Her strategy relies on her ability to navigate complex stakeholder relationships and her belief that the current healthcare system is too dysfunctional to change from within, necessitating an external, data-driven approach to human health. The success of this new iteration depends on her ability to scale the user base significantly and maintain public trust in the security of genetic data.